Skip to main content
SpringerLink
Log in

Furosemide pharmacokinetics and pharmacodynamics in health and disease—An update

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The literature on furosemide pharmacokinetics and pharmacodynamics is critically reviewed, concentrating on those papers published subsequent to the 1979 reviews of this topic. Intravenous and oral data are presented for healthy volunteers and for patients with various disease states. It is the latter populations about which the majority of the studies have been published since 1979. Inter- and intraindividual variations in bioavailability are discussed, as are data on the metabolism of furosemide to its glucuronide conjugate. Published studies examining the relationship between furosemide pharmacodynamics and pharmacokinetics are also evaluated. The literature is reviewed through June 1988.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. L. Z. Benet, Pharmacokinetics/pharmacodynamics of furosemide in man: A review.J. Pharmacokin. Biopharm. 7:1–27 (1979).

    CAS  Google Scholar 

  2. R. E. Cutler and A. D. Blair. Clinical pharmacokinetics of frusemide.Clin. Pharmacokin. 4:279–296 (1979).

    CAS  Google Scholar 

  3. C. Allgulander, B. Beermann, and A. Sjögren. Frusemide pharmacokinetics in patients with liver disease.Clin. Pharmacokin. 5:570–575 (1980).

    CAS  Google Scholar 

  4. F. Andreasen, C. Kjeldahl Christensen, F. Kjaer Jacobsen, J. Jansen, C. E. Mogensen, and O. Lederballe Pedersen. The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects.Eur. J. Clin. Invest. 12:247–255 (1982).

    CAS  PubMed  Google Scholar 

  5. F. Andreasen, U. Hansen, S. E. Husted, and J. A. Jansen. The pharmacokinetics of frusemide are influenced by age.Br. J. Clin. Pharmacol. 16:391–397 (1983).

    CAS  PubMed Central  PubMed  Google Scholar 

  6. D. C. Brater, R. Seiwell, S. Anderson, A. Burdette, G. J. Dehmer, and P. Chennavasin. Absorption and disposition of furosemide in congestive heart failure.Kidney Int. 22:171–176 (1982).

    CAS  PubMed  Google Scholar 

  7. G. Gonzalez, A. Arancibia, M. I. Rivas, P. Caro, and C. Antezana. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.Eur. J. Clin. Pharmacol. 22:315–320 (1982).

    CAS  PubMed  Google Scholar 

  8. A. Grahnén, M. Hammarlund, and T. Lundqvist. Implications of intraindividual variability in bioavailability studies of furosemide.Eur. J. Clin. Pharmacol. 27:595–602 (1984).

    PubMed  Google Scholar 

  9. M. Hammarlund, L. K. Paalzow, and B. Odlind. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.Eur. J. Clin. Pharmacol. 26:197–207 (1984).

    CAS  PubMed  Google Scholar 

  10. E. Keller, G. Hoppe-Seyler, and P. Schollmeyer. Disposition and diuretic effect of furosemide in the nephrotic syndrome.Clin. Pharmacol. Ther. 32:442–449 (1982).

    CAS  PubMed  Google Scholar 

  11. E. Keller, G. Hoppe-Seyler, R. Mumm, and P. Schollmeyer. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.Eur. J. Clin. Pharmacol. 20:27–33 (1981).

    CAS  PubMed  Google Scholar 

  12. C. Lambert, P. Larochelle, and P. duSouich. Effects of phenobarbital and tobacco smoking on furosemide kinetics and dynamics in normal subjects.Clin. Pharmacol. Ther. 34:170–175 (1983).

    CAS  PubMed  Google Scholar 

  13. V. K. Sawhney, P. B. Gregory, S. E. Swezey, and T. F. Blaschke. Furosemide disposition in cirrhotic patients.Gastroenterology 81:1012–1016 (1981).

    CAS  PubMed  Google Scholar 

  14. D. E. Smith, E. T. Lin, and L. Z. Benet. Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay.Drug Metab. Dispos. 8:337–342 (1980).

    CAS  PubMed  Google Scholar 

  15. R. K. Verbeeck, R. V. Patwardhan, J-P. Villeneuve, G. R. Wilkinson, and R. A. Branch. Furosemide disposition in cirrhosis.Clin. Pharmacol. Ther. 31:719–725 (1982).

    CAS  PubMed  Google Scholar 

  16. J-P. Villeneuve, R. K. Verbeeck, G. R. Wilkinson, and R. A. Branch. Furosemide kinetics and dynamics in patients with cirrhosis.Clin. Pharmacol. Ther. 40:14–20 (1986).

    CAS  PubMed  Google Scholar 

  17. E. S. Waller, S. F. Hamilton, J. W. Massarella, M. A. Sharanevych, R. V. Smith, G. J. Yakatan, and J. T. Doluishio. Disposition and absolute bioavailability of furosemide in healthy maies.J. Pharm. Sci. 71:1105–1108 (1982).

    CAS  PubMed  Google Scholar 

  18. J. Zhu and T. Koizumi. A study on furosemide disposition in man.J. Pharmacobiodyn. 10:370–376 (1987).

    CAS  PubMed  Google Scholar 

  19. W. Rupp and P. Hajdú. Pharmacokinetics and pharmacodynamics of a diuretic agent. In H. J. Dengler (ed.),Symposium on Pharmacological and Clinical Significance of Pharmacokinetics, F. K. Schattauer Verlag, Stuttgart, 1970, pp. 105–111.

    Google Scholar 

  20. A. L. Kerremans, Y. Tan, H. van Baars, C. A. M. van Ginneken, and F. W. J. Gribnau. Furosemide kinetics and dynamics in aged patients.Clin. Pharmacol. Ther. 34:181–189 (1983).

    CAS  PubMed  Google Scholar 

  21. W. Mühlberg, D. Platt, and E. Neubig. Pharmacokinetics and pharmacodynamics of furosemide in geriatric patients.Arch. Gerontol. Geriat. 5:249–263 (1986).

    Google Scholar 

  22. G. M. Pacifia, A. Viani, H.-U. Schulz, and H.-J. Frercks. Plasma protein binding of furosemide in the elderly.Eur. J. Clin. Pharmacol. 32:199–202 (1987).

    Google Scholar 

  23. A. Rane, J-P. Villeneuve, W. J. Stone, A. S. Nies, G. R. Wilkinson, and R. A. Branch. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia.Clin. Pharmacol. Ther. 24:199–207 (1978).

    CAS  PubMed  Google Scholar 

  24. D. E. Smith, M. L. Hyneck, R. R. Berardi, and F. K. Port. Urinary protein binding, kinetics, and dynamics of furosemide in nephrotic patients.J. Pharm. Sci,74:603–607 (1985).

    CAS  PubMed  Google Scholar 

  25. A. Greither, S. Goldman, J. S. Edelen, L. Z. Benet, and K. Cohn. Pharmacokinetics of furosemide in patients with congestive heart failure.Pharmacology 19:121–131 (1979).

    CAS  PubMed  Google Scholar 

  26. F. Andreasen and E. Mikkelsen. Distribution, elimination and effects of furosemide in normal subjects and in patients with heart failure.Eur. J. Clin. Pharmacol. 12:15–22 (1977).

    CAS  PubMed  Google Scholar 

  27. A. Nomura, H. Yasuda, K. Katoh, T. Akimoto, K. Miyazaki, and T. Arita. Hydralazine and furosemide kinetics.Clin. Pharmacol. Ther. 32:303–306 (1982).

    CAS  PubMed  Google Scholar 

  28. J. Perez, D. S. Sitar, and R. I. Ogilvie. Biotransformation of furosemide in patients with acute pulmonary edema.Drug Metab. Dispos. 7:383–387 (1979).

    CAS  PubMed  Google Scholar 

  29. J. Perez, D. S. Sitar, and R. I. Ogilvie. Kinetic disposition and diuretic effect of frusemide in acute pulmonary oedema.Br. J. Clin. Pharmacol. 9:471–478 (1980).

    CAS  PubMed Central  PubMed  Google Scholar 

  30. F. Andreasen, O. Lederballe Pedersen, and E. Mikkelsen. Distribution, elimination and natriuretic effect of furosemide in patients with severe arterial hypertension.Eur. J. Clin. Pharmacol. 14:237–244 (1978).

    CAS  PubMed  Google Scholar 

  31. F. Andreasen, H. E. Hansen, and E. Mikkelsen. Pharmacokinetics of furosemide in anephric patients and in normal subjects.Eur. J. Clin. Pharmacol 13:41–48 (1978).

    CAS  PubMed  Google Scholar 

  32. D. E. Smith, J. G. Gambertoglio, F. Vincenti, and L. Z. Benet. Furosemide kinetics and dynamics after kidney transplant.Clin. Pharmacol. Ther. 30:105–113 (1980).

    Google Scholar 

  33. B. Beermann, M. Groschinsky-Grind, L. Fåhraeus, and B. Lindström. Placental transfer of furosemide.Clin. Pharmacol. Ther. 24:560–562 (1978).

    CAS  PubMed  Google Scholar 

  34. P. Vert, M. Broquaire, M. Legagneur, and P. L. Morselli. Pharmacokinetics of furosemide in neonates.Eur. J. Clin. Pharmacol. 22:39–45 (1982).

    CAS  PubMed  Google Scholar 

  35. J. V. Aranda, J. Perez, D. S. Sitar, J. Collinge, A. Portuguez-Malavasi, B. Duffy, and C. Dupont. Pharmacokinetic disposition and protein binding of furosemide in newborn infants.J. Pediat. 93:507–511 (1978).

    CAS  PubMed  Google Scholar 

  36. R. G. Peterson, M. A. Simmons, B. H. Rumack, R. L. Levine, and J. G. Brooks. Pharmacology of furosemide in the premature newborn infant.J. Pediat. 97:139–143 (1980).

    CAS  PubMed  Google Scholar 

  37. M. H. Mirochnick, J. J. Miceli, P. A. Kramer, D. J. Chapron, and J. R. Raye. Furosemide pharmacokinetics in very low birth weight infants.J. Pediat. 112:653–657 (1988).

    CAS  PubMed  Google Scholar 

  38. S. Tuck, P. Morselli, M. Broquaire, and P. Vert. Plasma and urinary kinetics of furosemide in newborn infants.J. Pediat. 103:481–485 (1983).

    CAS  PubMed  Google Scholar 

  39. J. V. Aranda, C. Lambert, J. Perez, T. Turmen, and D. S. Sitar. Metabolism and renal elimination of furosemide in the newborn infant.J. Pediat. 101:777–781 (1982).

    CAS  PubMed  Google Scholar 

  40. G. Gonzalez-Martin, N. Ibarra, and A. Arancibia. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.Int. J. Clin. Pharmacol Ther. Toxicol. 21:598–601 (1983).

    CAS  PubMed  Google Scholar 

  41. J. Prandota. Urinary elimination kinetics and diuretic effect of intravenous furosemide in nephrotic children.Dev. Pharmacol. Ther. 5:98–108 (1982).

    CAS  PubMed  Google Scholar 

  42. J. Prandota. Pharmacokinetics of furosemide urinary elimination by nephrotic children.J. Pediat. Res. 17:141–147 (1983).

    CAS  Google Scholar 

  43. E. Riva, E. Fossali, and A. Bettinelli. Kinetics of furosemide in children with chronic renal failure undergoing regular hemodialysis.Eur. J. Clin. Pharmacol. 21:303–306 (1982).

    CAS  PubMed  Google Scholar 

  44. T. P. Green and B. L. Mirkin. Determinants of the diuretic response to furosemide in infants with congestive heart failure.Pediat. Cardiol. 3:47–51 (1982).

    CAS  Google Scholar 

  45. D. C. Brater, B. Day, A. Burdette, and S. Anderson. Bumetanide and furosemide in heart failure.Kidney Int. 26:183–189 (1984).

    CAS  PubMed  Google Scholar 

  46. H. Ogata, Y. Kawatsu, Y. Maruyama, K. Machida, and T. Haga. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.Eur. J. Clin. Pharmacol. 28:53–59 (1985).

    CAS  PubMed  Google Scholar 

  47. E. S. Waller, J. W. Massarella, M. S. Tomkiw, R. V. Smith, and J. T. Doluisio. Pharmacokinetics of furosemide after three different single oral doses.Biopharm. Drug Dispos. 6:109–117 (1985).

    CAS  PubMed  Google Scholar 

  48. A. B. Straughn, G. C. Wood, G. Raghow, and M. C. Meyer. Bioavailability of seven furosemide tablets in man.Biopharm. Drug Dispos. 7:113–120 (1986).

    CAS  PubMed  Google Scholar 

  49. P. J. McNamara, T. S. Foster, G. A. Digenis, R. B. Patel, W. A. Craig, P. G. Welling, R. S. Rapaka, V. K. Prasad, and V. P. Shah. Influence of tablet dissolution on furosemide bioavailability: A bioequivalence study.Pharmaceut. Res. 4:150–153 (1987).

    CAS  Google Scholar 

  50. M. R. Kelly, R. E. Cutler, A. W. Forrey, and B. M. Kimpel. Pharmacokinetics of orally administered furosemide.Clin. Pharmacol. Ther. 15:178–186 (1974).

    CAS  PubMed  Google Scholar 

  51. B. Beermann and C. Midskov. Reduced bioavailability and effect of furosemide given with food.Eur. J. Clin. Pharmacol. 29:725–727 (1986).

    CAS  PubMed  Google Scholar 

  52. B. Beermann. Kinetics and dynamics of furosemide and slow-acting furosemide.Clin. Pharmacol. Ther. 32:584–591 (1982).

    CAS  PubMed  Google Scholar 

  53. A. Ebihara, K. Tawara, and T. Oka. Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.Arzneimittel-Forsch. 33:163–166 (1983).

    CAS  Google Scholar 

  54. K. Uchino, S. Isozaki, J. Amano, N. Tanaka, Y. Saitoh, F. Nakagawa, Z. Tamura, and H. Oka. Clinical pharmacokinetics and diuretic effect of furosemide in plain tablet and retard capsule with normal subjects and cirrhotic patients.J. Pharmacobiodyn. 6:684–691 (1983).

    CAS  PubMed  Google Scholar 

  55. P. R. Chaturvedi, J. P. O'Donnel, J. M. Nicholas, D. R. Shoenthal, D. H. Waters, and P. R. Gwilt. Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure.Int. J. Clin. Pharmacol. Ther. Toxicol. 25:123–128 (1987).

    CAS  PubMed  Google Scholar 

  56. M. R. Vasko, D. Brown-Cartwright, J. P. Knochel, J. V. Nixon, and D. C. Brater. Furosemide absorption altered in decompensated congestive heart failure.Ann. Intern. Med. 102:314–318 (1985).

    CAS  PubMed  Google Scholar 

  57. B. K. Martin, M. Uihlein, R. M. J. Ings, L. A. Stevens, and J. McEwen. Comparative bioavailability of two furosemide formulations in humans.J. Pharm. Sci. 73:437–441 (1984).

    CAS  PubMed  Google Scholar 

  58. D. C. Brater, P. Chennavasin, B. Day, B. S. Burdette, and S. Anderson. Bumetanide and furosemide.Clin. Pharmacol. Ther. 34:207–213 (1983).

    CAS  PubMed  Google Scholar 

  59. H. J. Rogers, P. Morrison, F. R. House, and I. D. Bradbrook. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.Int. J. Clin. Pharmacol. Ther. Toxicol. 20:8–11 (1982).

    CAS  PubMed  Google Scholar 

  60. B. Beermann, E. Dalen, B. Lindström, and A. Rosen. On the fate of furosemide in man.Eur. J. Clin. Pharmacol. 9:57–61 (1985).

    Google Scholar 

  61. H. Kindt and E. Schmid. Über de Harnausscheidung von Furosemid bei Gesunden und Kranken mit Lebercirrhose.Pharmacol. Clin. 2:221–226 (1970).

    CAS  Google Scholar 

  62. A. Rachmel, G. A. Hazelton, A. L. Yergey, and D. J. Liberato. Furosemide 1-O-acyl glucuronide. In vitro biosynthesis and pH-dependent isomerization to beta-glucuronidase-resistant forms.Drug Metab. Dispos. 13:705–710 (1985).

    CAS  PubMed  Google Scholar 

  63. H. Sekikawa, T. Mizuma, E. T. Lin, and L. Z. Benet. Apparent intramolecular acyl migration and hydrolysis of furosemide glucuronide in aqueous solution.Pharmaceut. Res. (submitted 1988).

  64. L. Z. Benet, D. E. Smith, E. T. Lin, F. Vincenti, and J. G. Gambertoglio. Furosemide assays and disposition in healthy volunteers and renal transplant patients.Fed. Proc. 42:1695–1698 (1983).

    CAS  PubMed  Google Scholar 

  65. H. Nakahama, Y. Miwa, A. Yamaji, Y. Orita, Y. Fukuhara, M. Yanase, T. Kamada, T. Sonoda, M. Ishibasi, Y. Ichikawa, and S. Takahara. The urinary excretion of frusemide and its metabolites by kidney transplant patients.Eur. J. Clin. Pharmacol. 32:313–315 (1987).

    CAS  PubMed  Google Scholar 

  66. H. Sekikawa, E. T. Lin, and L. Z. Benet. Photodegradation of furosemide and furosemide glucuronide in aqueous solution.Pharmaceut. Res. (submitted 1988).

  67. D. E. Smith and L. Z. Benet. Biotransformation of furosemide in kidney transplant patients.Eur. J. Clin. Pharmacol. 24:787–790 (1983).

    CAS  PubMed  Google Scholar 

  68. F. Andreasen, C. Kjeldahl Christensen, F. Kjaer Jakobsen, and C. E. Mogensen. The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.Acta Pharmacol. Toxicol. 49:223–229 (1981).

    CAS  Google Scholar 

  69. A. Rakhit, G. M. Kochak, V. Tipnis, and M. E. Hurley. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.Clin. Pharmacol. Ther. 41:580–586 (1987).

    CAS  PubMed  Google Scholar 

  70. B. Beermann, E. Dalen, and B. Lindstrom. Elimination of furosemide in healthy subjects and in those with renal failure.Clin. Pharmacol. Ther. 22:70–78 (1977).

    CAS  PubMed  Google Scholar 

  71. W. Rupp. Pharmacokinetics and pharmacodynamics of lasix.Scot. Med. J. 19:5–13 (1974).

    PubMed  Google Scholar 

  72. J. F. Valentine, D. C. Brater, and G. J. Krejs. Clearance of furosemide by the gastrointestinal tract.J. Pharmacol. Exp. Ther. 236:177–180 (1986).

    CAS  PubMed  Google Scholar 

  73. M. G. Lee and W. L. Chiou. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.J. Pharmacokin. Biopharm. 11:623–640 (1983).

    CAS  Google Scholar 

  74. R. K. Verbeeck, J. F. Gerkens, G. R. Wilkinson, and R. A. Branch. Disposition of furosemide in functionally hepatectomized dogs.J. Pharmacol. Exp. Ther. 216:479–483 (1981).

    CAS  PubMed  Google Scholar 

  75. V. S. Chungi, L. W. Dittert, and R. B. Smith. Gastrointestinal sites of furosemide absorption in rats.Int. J. Pharm. 4:27–38 (1979).

    CAS  Google Scholar 

  76. D. C. Brater. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide.J. Pharmacol. Exp. Ther. 210:386–390 (1979).

    CAS  PubMed  Google Scholar 

  77. P. Chennavasin, R. Seiwell, and D. C. Brater. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man.J. Pharmacol. Exp. Ther. 215:77–81 (1980).

    CAS  PubMed  Google Scholar 

  78. R. E. Cutler, A. W. Forrey, T. G. Christopher, and B. M. Kimpel. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients.Clin. Pharmacol. Ther. 15:588–596 (1974).

    CAS  PubMed  Google Scholar 

  79. M. M. Hammarlund, B. Odlind, and L. K. Paalzow. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling.J. Pharmacol. Exp. Ther. 233:447–453 (1985).

    CAS  PubMed  Google Scholar 

  80. M. Homeida, C. Roberts, and R. A. Branch. Influence of probenecid and spironolactone on furosemide kinetics and dynamics in man.Clin. Pharmacol. Ther. 22:402–409 (1977).

    CAS  PubMed  Google Scholar 

  81. S. Kaojarern, B. Day, and D. C. Brater. The time course of delivery of furosemide into urine: an independent determinant of overall response.Kidney Int. 22:69–74 (1982).

    CAS  PubMed  Google Scholar 

  82. D. E. Smith, W. L. Gee, D. C. Brater, E. T. Lin, and L. Z. Benet. Preliminary evaluation of furosemide-probenecid interaction in humans.J. Pharm. Sci. 69:571–575 (1980).

    CAS  PubMed  Google Scholar 

  83. R. A. Branch, C. J. C. Roberts, M. Homeida, and D. Levine, Determinants of response to furosemide in normal subjects.Br. J. Clin. Pharmacol. 4:121–127 (1977).

    CAS  PubMed Central  PubMed  Google Scholar 

  84. J. Honari, A. D. Blair, and R. E. Cutler. Effects of probenecid on furosemide kinetics and natriuresis in man.Clin. Pharmacol. Ther. 22:395–401 (1977).

    CAS  PubMed  Google Scholar 

  85. M. R. Kelly, A. D. Blair, A. W. Forrey, N. A. Smidt, and R. A. Cutler. A comparison of the diuretic response to oral and intravenous furosemide in “diuretic-resistant” patients.Curr. Ther. Res. 21:1–9 (1977).

    CAS  PubMed  Google Scholar 

  86. B. Odlind and B. Beermann. Renal tubular secretion and effects of furosemide.Clin. Pharmacol. Ther. 27:784–790 (1980).

    CAS  PubMed  Google Scholar 

  87. T. W. Wilson, K. J. Falk, J. L. Labelle, and K. B. Nguyen. Effect of dosage regimen on natriuretic response to furosemide.Clin. Pharmacol. Ther. 18:165–169 (1975).

    CAS  PubMed  Google Scholar 

  88. D. C. Brater, P. Chennavasin, and R. Seiwell. Furosemide in patients with heart failure: shift in dose-response curves.Clin. Pharmacol. Ther. 28:182–186 (1980).

    CAS  PubMed  Google Scholar 

  89. D. C. Brater, S. A. Anderson and D. Brown-Cartwright. Response to furosemide in chronic renal insufficiency: rationale for limited doses.Clin. Pharmacol. Ther. 40:134–139 (1986).

    CAS  PubMed  Google Scholar 

  90. P. Chennavasin, R. Seiwell, D. C. Brater, and W. M. M. Liang. Pharmacodynamic analysis of the furosemide-probenecid interaction in man.Kidney Int. 16:187–195 (1979).

    CAS  PubMed  Google Scholar 

  91. A. Traeger, G. Stein, H. Sperschneider, and E. Keil. Pharmacokinetic and pharmacodynamic effects furosemide in patients with impaired renal function.Int. J. Clin. Pharmacol. Ther. Toxicol. 22:481–486 (1984).

    CAS  PubMed  Google Scholar 

  92. T. W. B. Gehr, D. A. Sica, D. C. Brater, J. Davis, and I. Fakhry. Furosemide pharmacokinetics and pharmacodynamics in renal transplantation.Clin. Pharmacol. Ther. 43:547–553 (1988).

    CAS  PubMed  Google Scholar 

  93. J. L. Data, A. Rane, J. Gerkens, G. R. Wilkinson, A. S. Nies, and R. A. Branch. The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog.J. Pharmacol. Exp. Ther. 206:431–438 (1978).

    CAS  PubMed  Google Scholar 

  94. M. G. Lee, T. Li, and W. L. Chiou. Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide.Biopharm. Drug Dispos. 7:537–547 (1986).

    CAS  PubMed  Google Scholar 

  95. L. E. Earlye and J. A. Martino. Influence of sodium balance on the ability of diuretics to inhibit tubular reabsorption; a study of the factors that influence renal and tubular reabsorption in man.Circulation 42:323–334 (1970).

    Google Scholar 

  96. J. G. Copeland, D. W. Campbell, J. R. Plachetka, N. W. Salomon, and D. F. Larson. Diuresis with continuous infusion of furosemide after cardiac surgery.Am. J. Surg. 146:796–799 (1983).

    CAS  PubMed  Google Scholar 

  97. M. Hammarlund and L. K. Paalzow. Acute tolerance development to the diuretic effect of furosemide in the rat.Biopharm. Drug Dispos. 6:9–21 (1985).

    CAS  PubMed  Google Scholar 

  98. T. Li, M. G. Lee, and W. L. Chiou. Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.J. Pharmacokin. Biopharm. 14:495–509 (1986).

    CAS  Google Scholar 

  99. P. A. Sjöström, B. G. Odlind, B. A. Beermann, and M. Hammarlund-Udenaes. On the mechanism of acute tolerance to furosemide diuresis.Scand. J. Urol. Nephrol. 22:133–140 (1988).

    PubMed  Google Scholar 

  100. J. Zhu and T. Koizumi. The diuretic effect of furosemide in relation to its disposition in man.J. Pharmacobiodyn. 10:377–383 (1987).

    CAS  PubMed  Google Scholar 

  101. F. Andreasen, U. Hansen, S. E. Husted, C. E. Mogensen, and E. B. Pedersen. The influence of age on renal and extrarenal effects of frusemide.Br. J. Clin. Pharmacol. 18:65–74 (1984).

    CAS  PubMed Central  PubMed  Google Scholar 

  102. A. Y. Chaudhry, R. F. Bing, C. M. Castleden, J. D. Swales, and C. J. Napier. The effect of ageing on the response to frusemide in normal subjects.Eur. J. Clin. Pharmacol. 27:303–306 (1984).

    CAS  PubMed  Google Scholar 

  103. R. Fuller, C. Hoppel, and S. T. Ingalls. Furosemide kinetics in patients with hepatic cirrhosis with ascites.Clin. Pharmacol. Ther. 30:461–467 (1981).

    CAS  PubMed  Google Scholar 

  104. M. Pinzani, G. Daskalopoulos, G. Laffi, P. Gentilini, and R. D. Zipser. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance.Gastroenterology 92:294–298 (1987).

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Margareta Hammarlund-Udenaes

    Present address: Department of Biopharmaceutics and Pharmacokinetics, University of Uppsala, Sweden

Authors and Affiliations

  1. Department of Pharmacy, School of Pharmacy, University of California, 94143-0446, San Francisco, California

    Margareta Hammarlund-Udenaes & Leslie Z. Benet

Authors
  1. Margareta Hammarlund-Udenaes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie Z. Benet
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported in part by National Institutes of Health grants GM26691 and GM36633.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammarlund-Udenaes, M., Benet, L.Z. Furosemide pharmacokinetics and pharmacodynamics in health and disease—An update. Journal of Pharmacokinetics and Biopharmaceutics 17, 1–46 (1989). https://doi.org/10.1007/BF01059086

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059086

Key words

Search

Navigation